New ultrasound contrast agent could spot liver cancer sooner
NCT ID NCT07590284
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test whether using a contrast agent called Sonazoid during ultrasound can find early-stage liver cancer better than standard ultrasound alone. About 556 adults with liver cirrhosis will be scanned every 4 to 6 months. The goal is to see if this method catches more cancers at an early, treatable stage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sonazoid contrast agent for ultrasound
What this could lead to
If successful, this could improve early detection of liver cancer in high-risk patients, potentially saving lives through earlier treatment.
What could go wrong
This is an early-stage diagnostic study, not a treatment trial. The new method may not prove more effective than current imaging, and results may not apply to all liver disease patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Third Central Hospital
Tianjin, Tianjin Municipality, 300170, China